DARZALEX (Janssen Biotech, Inc.)
Welcome to the PulseAid listing for the DARZALEX drug offered from Janssen Biotech, Inc.. This CD38-directed Cytolytic Antibody [EPC],CD38-directed Antibody Interactions [MoA],Antibodies, Monoclonal [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Janssen Biotech, Inc. |
| NON-PROPRIETARY NAME: | Daratumumab |
| SUBSTANCE NAME: | DARATUMUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | CD38-directed Cytolytic Antibody [EPC],CD38-directed Antibody Interactions [MoA],Antibodies, Monoclonal [Chemical/Ingredient] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION, CONCENTRATE |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2015-11-16 |
| END MARKETING DATE: | 0000-00-00 |
DARZALEX HUMAN PRESCRIPTION DRUG Details:
| Item Description | DARZALEX from Janssen Biotech, Inc. |
| LABELER NAME: | Janssen Biotech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100(mg/5mL) |
| START MARKETING DATE: | 2015-11-16 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 57894-502_7e98faf7-ed1d-49c6-adee-50b09f9684f0 |
| PRODUCT NDC: | 57894-502 |
| APPLICATION NUMBER: | BLA761036 |
Other DARATUMUMAB Pharmaceutical Manufacturers / Labelers:
